摘要
目的分析依帕司他联合胰激肽原酶治疗2型糖尿病周围神经病变临床效果及对炎性因子、肌电图指标的影响。方法回顾性分析2019年9月—2021年2月收治的2型糖尿病周围神经病变102例的临床资料,按照治疗方式分为研究组53例和对照组49例。对照组给予胰激肽原酶治疗,研究组在对照组基础上给予依帕司他治疗。观察2组临床疗效,比较2组治疗前后炎性因子水平、肌电图指标。记录2组不良反应发生情况。结果研究组总有效率高于对照组(P<0.05)。治疗后2组C反应蛋白、白细胞介素-6、降钙素原水平均低于对照组,且研究组低于对照组(P<0.05,P<0.01);治疗后,2组正中神经、腓总神经运动神经传导速度和感觉神经传导速度均较治疗前增加,且研究组大于对照组(P<0.05,P<0.01)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论对2型糖尿病周围神经病变患者采用依帕司他联合胰激肽原酶治疗临床效果确切,可显著降低炎性因子水平,改善神经传导速度,且安全可靠。
Objective To analyze clinical efficacy of Epalrestat combined with Pancreatic Kininogenase in treatment of patients with type 2 diabetic peripheral neuropathy(T2DPN)and their effects on inflammatory factors and electromyographic(EMP)indexes.Methods Clinical data of 102 patients with T2DPN admitted between September 2019 and February 2021 was retrospectively analyzed,and the patients were divided into research group(n=53)and control group(n=49)according to different therapeutic methods.Control group was treated with Pancreatic Kininogenase,while research group was treated with Epalrestat on the basis of treatment for control group.Clinical efficacy was observed,and levels of inflammatory factors and electromyogram(EMG)indexes before and after treatment were compared between two groups.Conditions of adverse reactions were recorded in two groups.Results The total effective rate in research group was significantly higher than that in control group(P<0.05).After treatment,levels of C-reactive protein(CRP),interleukin-6(IL-6)and procalcitonin were significantly lower than those before treatment in two groups,and the levels in research group were significantly lower than those in control group(P<0.05,P<0.01).After treatment,values of motor nerve conduction velocity and sensory nerve conduction velocity of median nerve and common peroneal nerve were significantly higher than those before treatment in two groups,and the values in research group were significantly higher than those in control group(P<0.05,P<0.01).There was no statistically significant difference in incidence rate of adverse reactions between two groups(P>0.05).Conclusion Epalrestat combined with Pancreatic Kininogenase in treatment of patients with T2DPN may achieve a definite clinical efficacy,significantly reduce levels of inflammatory factors and improve nerve conduction velocity with safe and reliable.
作者
倪孝兵
王思宏
黄崇兵
NI Xiao-bing;WANG Si-hong;HUANG Chong-bing(Department of Endocrinology,People's Hospital of Xuancheng City,Xuancheng,Anhui 242000,China)
出处
《解放军医药杂志》
CAS
2022年第4期88-91,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
安徽省科技攻关项目(1801042235)。
作者简介
倪孝兵,本科,主治医师。主要从事内分泌及代谢性疾病方向研究。
